{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Growth&page=53",
    "query": {
      "condition": "Growth",
      "page": 53
    },
    "page_size": 10
  },
  "pagination": {
    "page": 53,
    "page_size": 10,
    "total_count": 1659,
    "total_pages": 166,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Growth&page=54&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Growth&page=52&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-28T14:24:17.180Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00622726",
      "title": "Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Retinopathy of Prematurity"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Conventional Laser for ROP",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "The University of Texas Health Science Center, Houston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Weeks",
        "maximum_age": "22 Weeks",
        "sex": "ALL",
        "summary": "4 Weeks to 22 Weeks"
      },
      "enrollment_count": 150,
      "start_date": "2008-03",
      "completion_date": "2020-08",
      "has_results": true,
      "last_update_posted_date": "2017-06-06",
      "last_synced_at": "2026-10-28T14:24:17.180Z",
      "location_count": 15,
      "location_summary": "Pasadena, California • Denver, Colorado • Peoria, Illinois + 7 more",
      "locations": [
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Columbia",
          "state": "South Carolina"
        },
        {
          "city": "Columbia",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00622726"
    },
    {
      "nct_id": "NCT03234712",
      "title": "A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors Cancer"
      ],
      "interventions": [
        {
          "name": "ABBV-321",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 62,
      "start_date": "2017-10-10",
      "completion_date": "2021-04-14",
      "has_results": false,
      "last_update_posted_date": "2021-05-06",
      "last_synced_at": "2026-10-28T14:24:17.180Z",
      "location_count": 14,
      "location_summary": "Springdale, Arkansas • Los Angeles, California • Sacramento, California + 10 more",
      "locations": [
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03234712"
    },
    {
      "nct_id": "NCT04579328",
      "title": "Impact of Life-size Growth Charts on Understanding of Stunting",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Stunting"
      ],
      "interventions": [
        {
          "name": "Exposure to Growth Mats",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Tufts University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1019,
      "start_date": "2020-10-15",
      "completion_date": "2021-07",
      "has_results": false,
      "last_update_posted_date": "2021-05-06",
      "last_synced_at": "2026-10-28T14:24:17.180Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04579328"
    },
    {
      "nct_id": "NCT00063401",
      "title": "Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Peritoneal Neoplasms",
        "Fallopian Tube Neoplasms"
      ],
      "interventions": [
        {
          "name": "Cetuximab:",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 39,
      "start_date": "2003-09",
      "completion_date": "2006-06",
      "has_results": false,
      "last_update_posted_date": "2010-04-08",
      "last_synced_at": "2026-10-28T14:24:17.180Z",
      "location_count": 2,
      "location_summary": "New York, New York • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00063401"
    },
    {
      "nct_id": "NCT00233519",
      "title": "Effects of SomatoKine (Iplex)Recombinant Human Insulin-like Growth Factor-1/Recombinant Human Insulin-like Growth Factor-binding Protein-3 (rhIGF-I/rhIGFBP-3) in Myotonic Dystrophy Type 1 (DM1)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Myotonic Dystrophy"
      ],
      "interventions": [
        {
          "name": "SomatoKine/IPLEX",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Rochester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "21 Years to 60 Years"
      },
      "enrollment_count": 17,
      "start_date": "2005-11",
      "completion_date": "2008-05",
      "has_results": true,
      "last_update_posted_date": "2012-06-25",
      "last_synced_at": "2026-10-28T14:24:17.180Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00233519"
    },
    {
      "nct_id": "NCT00327444",
      "title": "Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Ovarian Neoplasms",
        "Ascites"
      ],
      "interventions": [
        {
          "name": "aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 58,
      "start_date": "2006-07",
      "completion_date": "2009-10",
      "has_results": true,
      "last_update_posted_date": "2013-01-01",
      "last_synced_at": "2026-10-28T14:24:17.180Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00327444"
    },
    {
      "nct_id": "NCT03426644",
      "title": "Mobile Health Sleep and Growth Study 2",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Childhood Sleep Promotion"
      ],
      "interventions": [
        {
          "name": "Mobile Sleep and Growth Study",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Children's Hospital of Philadelphia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "10 Years to 12 Years"
      },
      "enrollment_count": 44,
      "start_date": "2018-02-26",
      "completion_date": "2018-12-17",
      "has_results": false,
      "last_update_posted_date": "2023-01-17",
      "last_synced_at": "2026-10-28T14:24:17.180Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03426644"
    },
    {
      "nct_id": "NCT07462377",
      "title": "A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Epidermal Growth Factor",
        "Epidermal Growth Factor Receptor",
        "Epidermal Growth Factor Receptor Gene Mutation",
        "Non Small Cell",
        "Non Small Cell Lung",
        "Non Small Cell Lung Cancer",
        "Head and Neck",
        "Head and Neck Cancer",
        "Head and Neck Cancers",
        "Head and Neck Squamous Cell Cancer",
        "Head and Neck Squamous Cell Carcinoma",
        "Head and Neck Squamous Cell Carcinoma HNSCC",
        "NSCLC (Non-small Cell Lung Cancer)",
        "HNSCC",
        "EGFR"
      ],
      "interventions": [
        {
          "name": "EPI-326",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EpiBiologics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 110,
      "start_date": "2026-03-31",
      "completion_date": "2029-07",
      "has_results": false,
      "last_update_posted_date": "2026-10-14",
      "last_synced_at": "2026-10-28T14:24:17.180Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • East Brunswick, New Jersey • Lake Success, New York + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "East Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "Lake Success",
          "state": "New York"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07462377"
    },
    {
      "nct_id": "NCT00957671",
      "title": "Anterior Pituitary Hormone Replacement in Traumatic Brain Injury",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Growth Hormone Deficiency",
        "Traumatic Brain Injury"
      ],
      "interventions": [
        {
          "name": "Recombinant human growth hormone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The University of Texas Medical Branch, Galveston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2003-11",
      "completion_date": "2015-10",
      "has_results": true,
      "last_update_posted_date": "2018-06-29",
      "last_synced_at": "2026-10-28T14:24:17.180Z",
      "location_count": 2,
      "location_summary": "Galveston, Texas",
      "locations": [
        {
          "city": "Galveston",
          "state": "Texas"
        },
        {
          "city": "Galveston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00957671"
    },
    {
      "nct_id": "NCT01943084",
      "title": "A Trial to Investigate the Bioequivalence of Norditropin® (Somatropin) Versus Genotropin® (Somatropin) in Healthy Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Growth Disorder",
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Norditropin® FlexPro® pen",
          "type": "DRUG"
        },
        {
          "name": "Genotropin Pen®",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 32,
      "start_date": "2013-09",
      "completion_date": "2013-10",
      "has_results": false,
      "last_update_posted_date": "2015-03-19",
      "last_synced_at": "2026-10-28T14:24:17.180Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01943084"
    }
  ]
}